Callan Family Office LLC Purchases New Position in Zimmer Biomet Holdings, Inc. $ZBH

Callan Family Office LLC acquired a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 2nd quarter, Holdings Channel reports. The fund acquired 66,996 shares of the medical equipment provider’s stock, valued at approximately $5,768,000.

Several other hedge funds also recently bought and sold shares of ZBH. DV Equities LLC bought a new position in shares of Zimmer Biomet during the fourth quarter worth $25,000. Tacita Capital Inc acquired a new stake in Zimmer Biomet during the 2nd quarter worth $26,000. Monetary Solutions Ltd acquired a new position in Zimmer Biomet in the fourth quarter valued at about $30,000. Gen Wealth Partners Inc acquired a new position in Zimmer Biomet in the fourth quarter valued at about $31,000. Finally, Elevation Wealth Partners LLC increased its holdings in shares of Zimmer Biomet by 145.9% in the second quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock worth $33,000 after acquiring an additional 229 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research report on Wednesday, August 5th. Barclays lowered their target price on Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a research note on Wednesday, April 29th. Citigroup dropped their target price on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a report on Thursday, May 28th. Citizens Jmp cut their price target on shares of Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating on the stock in a research note on Wednesday, April 29th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a report on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $104.42.

Insiders Place Their Bets

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the transaction, the insider owned 27,251 shares of the company’s stock, valued at $2,252,022.64. This represents a 15.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.28% of the stock is currently owned by company insiders.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock opened at $101.01 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94. The firm has a market cap of $19.27 billion, a price-to-earnings ratio of 24.58, a price-to-earnings-growth ratio of 2.69 and a beta of 0.45. The stock’s 50-day moving average is $92.64 and its 200-day moving average is $91.00. Zimmer Biomet Holdings, Inc. has a one year low of $79.12 and a one year high of $108.29.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The business had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. During the same period last year, the company earned $2.07 earnings per share. Zimmer Biomet’s quarterly revenue was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current fiscal year.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.